Home

Pfizer (PFE)

25.38
+0.06 (0.24%)
NYSE · Last Trade: Jul 4th, 7:20 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close25.32
Open25.35
Bid25.40
Ask25.43
Day's Range25.22 - 25.52
52 Week Range20.92 - 31.54
Volume27,104,635
Market Cap142.30B
PE Ratio (TTM)18.39
EPS (TTM)1.4
Dividend & Yield1.720 (6.78%)
1 Month Average Volume38,329,230

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

2 Stocks to Buy With Less Than $50fool.com
Via The Motley Fool · July 4, 2025
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Reportbenzinga.com
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
Via Benzinga · July 4, 2025
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028fool.com
The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived.
Via The Motley Fool · July 4, 2025
3 Safe-and-Steady Stocks on Our Watchlist
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals. These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over time.
Via StockStory · July 4, 2025
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session.chartmill.com
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · July 3, 2025
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approvalbenzinga.com
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.
Via Benzinga · July 3, 2025
Recent Report Shows That Sen. Ron L Wyden Sold Up to $15K Worth of Pfizer Stockbenzinga.com
Via Benzinga · July 3, 2025
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yieldsbenzinga.com
Via Benzinga · July 3, 2025
Is Pfizer Stock a Yield Trap?fool.com
Via The Motley Fool · July 3, 2025
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in Julyfool.com
Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer.
Via The Motley Fool · July 3, 2025
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panelstocktwits.com
The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.
Via Stocktwits · July 2, 2025
Huge Unusual Volume In Pfizer Put Options Signals Investors Bullish Outlooktalkmarkets.com
Large unusual trading volume in Pfizer, Inc. put options that expire 30 days from now signals investors' bullish outlook on PFE stock.
Via Talk Markets · July 2, 2025
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasonsbenzinga.com
Via Benzinga · July 2, 2025
2 of Wall Street’s Favorite Stocks to Research Further and 1 to Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Via StockStory · July 2, 2025
Curious about the most active S&P500 stocks in today's session?chartmill.com
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · July 1, 2025
Dynamic Global Events Presents: The 6th Clinical Trial Agreements Summit
Dynamic Global Events (“DGE”) is proud to announce the 6th Clinical Trial Agreements Summit taking place August 21-22 in Philadelphia. This event will explore how to negotiate budgetary restraints, protect intellectual property and clinical data, and reduce risks in indemnification and subject injury.
Via Investor Brand Network · July 1, 2025
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Electionstocktwits.com
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.
Via Stocktwits · June 30, 2025
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?investors.com
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
3 No-Brainer Stocks to Buy for Under $100 Right Nowfool.com
Via The Motley Fool · June 28, 2025
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarmstocktwits.com
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.
Via Stocktwits · June 26, 2025
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Databenzinga.com
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.
Via Benzinga · June 26, 2025
Tesla Senior Executive And Elon Musk Confidant Omead Afshar Leaves EV Giant Amid Dropping Sales, Days After Robotaxi Launch: Reportstocktwits.com
Afshar was promoted last year to oversee sales and manufacturing operations in North America and Europe. He previously worked in the office of the CEO.
Via Stocktwits · June 26, 2025
Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodiesstocktwits.com
During the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in annualized bleeding rate in 12 months.
Via Stocktwits · June 26, 2025
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed.1,2,3,4
By Pfizer Inc. · Via Business Wire · June 26, 2025
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Groupbenzinga.com
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts.
Via Benzinga · June 26, 2025